These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 15325601)

  • 1. Lopinavir/ritonavir- and indinavir-induced thrombocytopenia in a patient with HIV infection.
    Colebunders R; De Schacht C; Vanwolleghem T; Callens S
    Int J Infect Dis; 2004 Sep; 8(5):315-6. PubMed ID: 15325601
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy.
    Antoniou T; Park-Wyllie L; Boyle E
    J Acquir Immune Defic Syndr; 2004 Dec; 37(5):1666-7. PubMed ID: 15577427
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
    Justesen US; Fox Z; Pedersen C; Cahn P; Gerstoft J; Clumeck N; Losso M; Peters B; Obel N; Castagna A; Dragsted UB; Lundgren JD;
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):339-44. PubMed ID: 17910618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient.
    Touzot M; Beller CL; Touzot F; Louet AL; Piketty C
    AIDS; 2006 May; 20(8):1210-2. PubMed ID: 16691080
    [No Abstract]   [Full Text] [Related]  

  • 5. Acquired macroglossia due to lopinavir/ritonavir treatment.
    Vritsali E; Kolokotronis A; Valagouti D; Miteloudis G; Zaraboukas T; Kioses V; Antoniades D
    J Oral Pathol Med; 2005 Jan; 34(1):56-8. PubMed ID: 15610408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyponatraemia associated with lopinavir--ritonavir?
    Roberts MT; Aliyu SH
    Int J Infect Dis; 2007 Jan; 11(1):83-4. PubMed ID: 16574455
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.
    Resino S; Bellón JM; Muñoz-Fernández MA;
    J Antimicrob Chemother; 2006 Mar; 57(3):579-82. PubMed ID: 16446377
    [No Abstract]   [Full Text] [Related]  

  • 8. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [From HAART to "smart": maximizing the advantages of lopinavir/ritonavir].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():68-9. PubMed ID: 15373055
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for ritonavir intolerance and outcome after change to indinavir.
    Casado JL; Perez-Elías MJ; Antela A; Martí-Belda P; de Lucas S; Muñoz V; Guerrero A
    AIDS; 1998 Feb; 12(3):335-6. PubMed ID: 9580044
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
    TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
    [No Abstract]   [Full Text] [Related]  

  • 13. Indinavir and thrombocytopenia.
    Durand JM
    AIDS; 1999 Jan; 13(1):148-9. PubMed ID: 10207566
    [No Abstract]   [Full Text] [Related]  

  • 14. Ritonavir and indinavir one year later.
    TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
    [No Abstract]   [Full Text] [Related]  

  • 15. Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.
    Chrysos G; Mikros S; Kokkoris S; Pastelli A; Kontochristopoulos G
    J Drugs Dermatol; 2007 Jul; 6(7):742-3. PubMed ID: 17763601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
    von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
    Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.
    Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
    Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
    J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients.
    Chronister CL; Gurwood AS
    J Am Optom Assoc; 1998 Nov; 69(11):695-8. PubMed ID: 9844321
    [No Abstract]   [Full Text] [Related]  

  • 20. Interaction between lopinavir/ritonavir and warfarin.
    Hughes CA; Freitas A; Miedzinski LJ
    CMAJ; 2007 Aug; 177(4):357-9. PubMed ID: 17698824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.